OrbusNeich Medical Technology Co. Ltd.

DUBLIN--( BUSINESS WIRE )--The "Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive information about the Bioabsorbable Stents (BAS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Bioabsorbable stents are also known as bioreabsorbable or biodegradable coronary stents. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents. Scope Extensive coverage of the Bioabsorbable Stents (BAS) under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment/industry Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Bioabsorbable Stents (BAS) Overview 3 Products under Development 3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory 3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies 4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 5 Bioabsorbable Stents (BAS) Companies and Product Overview 5.1 Abbott Vascular Inc Company Overview 5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 5.2 Amaranth Medical Inc Company Overview 5.3 Arterius Ltd Company Overview 5.4 Biosensors International Group Ltd Company Overview 5.5 Biosten, LLC Company Overview 5.6 Biotronik AG Company Overview 5.7 Biotronik SE & Co KG Company Overview 5.8 Biotyx Medical (Shenzhen) Co Ltd Company Overview 5.9 Boston Scientific Corp Company Overview 5.10 Cardionovum GmbH Company Overview 5.11 Cordis Corp Company Overview 5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 5.13 Icon Interventional Systems, Inc. Company Overview 5.14 Japan Stent Technology Co., Ltd. Company Overview 5.15 Kyoto Medical Planning Co Ltd Company Overview 5.16 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 5.17 Manli Cardiology Ltd Company Overview 5.18 Meril Life Sciences Pvt Ltd Company Overview 5.19 Micell Technologies Inc Company Overview 5.20 Michigan Technological University Company Overview 5.21 MicroPort Scientific Corp Company Overview 5.22 Minvasys SAS Company Overview 5.23 MIV Therapeutics Inc Company Overview 5.24 NanoCoeur, Inc. Company Overview 5.25 North Carolina State University Company Overview 5.26 Northwestern University Company Overview 5.27 OrbusNeich Company Overview 5.28 Pediastent LLC Company Overview 5.29 QualiMed Innovative Medizinprodukte GmbH Company Overview 5.30 REVA Medical Inc Company Overview 5.31 S3V Vascular Technologies Company Overview 5.32 Shanghai Bio-heart Biological Technology Co Ltd Company Overview 5.33 Shanghai Healing Medical Instruments Co Ltd Company Overview 5.34 Tepha Inc Company Overview 5.35 Tremedics Medical Devices LLC Company Overview 5.36 UAB Minority Health and Health Equity Research Center Company Overview 5.37 University of Florida Company Overview 5.38 University of Strathclyde Company Overview 5.39 VasoTech Inc. Company Overview 5.40 Xenogenics Corporation Company Overview 6 Bioabsorbable Stents (BAS)- Recent Developments 6.1 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million 6.2 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023 6.3 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022 6.4 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022 6.5 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule 6.6 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022 6.7 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022 7 Appendix For more information about this report visit https://www.researchandmarkets.com/r/d7bf3z About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CSI provides devices for atherectomy, a minimally invasive treatment for removing plaque accumulated in arteries, and has an early-stage pipeline of complementary vascular intervention devices Abbott to acquire CSI. (Credit: jesse orrico on Unsplash) US-based medical technology company Abbott has signed a definitive agreement to acquire cardiovascular devices maker Cardiovascular Systems (CSI) to boost its vascular offerings. Under terms of the agreement, CSI stockholders are expected to receive $20 for CSI common share held, for a total equity value of around $890m. The transaction has been approved by the boards of directors of both CSI and Abbott. Its closing is subject to the approval of CSI stockholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. Abbott medical devices executive vice president Lisa Earnhardt said: “The acquisition of CSI will add new, complementary technologies to Abbott’s leading vascular device offerings. “CSI has a talented and experienced team and a leading atherectomy system that will allow Abbott to provide physicians more tools to help patients live fuller lives.” CSI is engaged in providing devices for atherectomy, a minimally invasive treatment for removing plaque accumulated in arteries that can restrict blood flow. Atherectomy procedures may enhance the benefits of standard balloon angioplasty or stent treatments in restoring blood flow in complex arterial disease. CSI also has an early-stage pipeline of complementary vascular intervention devices currently under development. In January last year, CSI has announced the commercialisation of its intravascular lithotripsy (IVL) systems for the treatment of calcific coronary and peripheral artery disease. Together with its partner OrbusNeich Medical, CSI has secured the US Food and Drug Administration (FDA) premarket approval (PMA) for the Scoreflex scoring balloon. CSI chairman, president, and chief executive officer Scott Ward said: “We are pleased to have reached an agreement with a leading global company that shares our passion for the development and commercialization of innovative solutions for treating complex peripheral vascular disease and coronary artery disease. “We believe combining with Abbott delivers value to our patients, physician customers, employees and stockholders while continuing our work to save limbs and save lives every day.”